Nonmotor disorders and their correlation with dopamine: Can they be treated by currently available methods?

Neurologist

Volumn 17, Issue 6 SUPPL., 2011, Pages

  Martinez Castrillo, Juan Carlos ^a   Vela, Lydia ^b   Del Val, Javier ^c   Alonso Canovas, Araceli ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

Author keywords

dopamine; dopaminergic therapy; fluctuations; nonmotor symptoms; pain; Parkinson disease

Indexed keywords

ALPRAZOLAM; ANTIHYPERTENSIVE AGENT; APOMORPHINE; BENZODIAZEPINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CAPTOPRIL; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUDROCORTISONE; INDOMETACIN; LAXATIVE; LEVODOPA; LORAZEPAM; MACROGOL; METHYLPHENIDATE; MIDODRINE; MODAFINIL; OSMOTIC AGENT; PERGOLIDE; PROPRANOLOL; PYRIDOSTIGMINE; ROPINIROLE; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ANORGASMIA; ANTIHYPERTENSIVE THERAPY; ANXIETY DISORDER; APATHY; ARTICLE; ASTHENIA; BLADDER DYSFUNCTION; BRAIN DEPTH STIMULATION; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; DAYTIME SOMNOLENCE; DEPRESSION; DOPAMINERGIC ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DYSAUTONOMIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPERSALIVATION; HYPERSEXUALITY; HYPERTENSION; IMPOTENCE; IMPULSE CONTROL DISORDER; LIBIDO DISORDER; MEMORY DISORDER; NOCTURIA; ORTHOSTATIC HYPOTENSION; PAIN; PAIN ASSESSMENT; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SIDE EFFECT; URINE INCONTINENCE;

AUTONOMIC NERVOUS SYSTEM DISEASES; COGNITION DISORDERS; DOPAMINE; GAMBLING; HUMANS; MENTAL DISORDERS; PAIN; PARKINSON DISEASE;

EID: 80455131107     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e318239669f     Document Type: Article

References (123)

1. Loeffler DA, LeWitt PA, Juneau PL, et al. Influence of repeated levodopa administration on rabbit striatal serotonin metabolism, and comparison between striatal and CSF alterations. Neurochem Res. 1998;23:1521-1525.
2. Politis M, Piccini P, Pavese N, et al. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: An in vivo 11C-raclopride study. Exp Neurol. 2008; 214:112-116.
3. Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson's disease: Dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8:464-474.
4. Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson's disease: Diagnosis and management. Lancet Neurol. 2006;5:235-245.
5. Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice parameter: Treatment of nonmotor symptoms of Parkinson disease. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74:924-931.
6. Tolosa E, Compta Y, Semedo C. Non-motor symptoms: Redefining Parkinson's disease. In: Martinez Martin P, Sanchez Andres JV, eds. Non-motor symptoms in Parkinson's disease. Viguera Editors SL. Barcelona, 2009:1-12.
7. Witjas T, Kaphan E, Azulay JP. Nonmotor fluctuations in Parkinson's disease: Frequent and disabling. Neurology. 2002;59: 408-413.
8. Witjas T, Kaphan E, Azulay JP. Non-motor fluctuations in Parkinson's disease. Rev Neurol. 2007;163:846-850.
9. Witjas T, Kaphan E, Regis J. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's Disease. Mov Disord. 2007;22:1729-1735.
10. Stacy M, Bowron A, Guttman M. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord. 2005;20:726-733.
11. Honig H, Antonini A, Martinez-Martin P. Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicentre study of effects on non-motor symptoms and quality of life. Mov Disord. 2009;24:1468-1474.
12. Singer W, Opfer-Gehrking TL, McPhee BR, et al. Acetylcholinesterase inhibition: A novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2003;74:1294-1298.
13. Ziemssen T, Reichmann H. Treatment of dysautonomia in extrapyramidal disorders. Ther Adv Neurol Disord. 2010;3:53-67.
14. Magerkurth C, Schnitzer R, Braune S. Symptoms of autonomic failure in Parkinson's disease: Prevalence and impact on daily life. Clin Auton Res. 2005;15:76-82.
15. Chaudhuri KR, Odin P, Antonini A, et al. Parkinson's disease: The non-motor issues. Parkinsonism Relat Disord. 2011. (Epub ahead of print).
16. Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: Mechanisms, prevalence, symptoms, and management. Mov Disord. 2006;21:737-745.
17. Christmas T, Kempster P, Chapple C. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet. 1988; 2:1451-1453.
18. Yoshimura N, Mizuta E, Yoshida O, et al. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J Pharmacol Exp Ther. 1998;286: 228-233.
19. Uchiyama T, Sakakibara R, Hattori T, et al. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon. Mov Disord. 2003;18:573-578.
20. Yoshimura N, Sass M, Yoshida O, et al. Dopamine D1 receptor mediated inhibition of micturition reflex by central dopamine from the substantia nigra. Neurourol Urodyn. 1992;11:535-545.
21. Seki S, Igawa Y, Kaidoh K, et al. Role of dopamine D1 and D1 receptors in the micturition reflex in conscious rats. Neurourology Urodyn. 2001;20:105-113.
22. Martinez-Martin P, Schapira AHV, Stocchi F. Prevalence of non motor symptoms in Parkinson's disease in an international setting; study using non-motor symptoms questionnaire in 545 patients. Mov Disord. 2007;22:1623-1629.
23. Seif C, Herzog J, van der Horst C. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol. 2004;55:118-120.
24. Shimizu N, Matsumoto S, Mori Y. Effects of deep brain stimulation on urodynamic findings in patients with Parkinson's disease. Hinyokika Kiyo. 2007;53:609-612.
25. Giladi N, Mair KJ, Badenhorst F, et al. Effects of rotigotine transdermal patch on early morning motor function, sleep quality and daytime sleepiness in patients with idiopathic disease results of a multicenter, multinational trial (abstract). Eur J Neurol. 2006;13:74.
26. Metta V, Naidu Y, Muzerengi S. The beneficial effect of rotigotine transdermal patch on nocturia in Parkinson's disease. 6th International Congress on Mental Dysfunctions and Other Non Motor Features in Parkinson's Disease, Dresden, October. Park Relat Disord. 2008;abstract P01:51.
27. Klos KJ, Bower JH, Josephs KA, et al. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Park Relat Disord. 2005;11:381-386.
28. O'Sullivan JD, Hughes AJ. Apomorphine induced penile erections in Parkinson's disease. Mov Disord. 1998;13:536-539.
29. Dula E, Bukofzer S, Perdok R. Double blind crossover comparison of 3 mg apomorphine SL with placebo and with 4mg apomorphine SL in male erectile dysfunction. Eur Urol. 2001;39:558-564.
30. Hussain IF, Brady CM, Swinn MJ, et al. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2001;71:371-374.
31. Singharam C, Ashraf W, Gaummitz EA. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet. 1995;346:861-864.
32. Abbott RD, Petrovitch H, White LR. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology. 2001;57:456-462.
33. Edwards LL, Quigley EMM, Harned RK, et al. Defecatory function in Parkinson's disease: Response to apomorphine. Ann Neurol. 1993;33:490-493.
34. Zangaglia R, Martignoni E, Glorioso M. Macrogol for the treatment of constipation in Parkinson's disease: A randomized placebo-controlled study. Mov Disord. 2007;22:1239-1244.
35. Albanese A, Brisinda G, Bentivoglio AR, et al. Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. Am J Gastroenterol. 2003;98:1439-1440.
36. Barichella M, Cereda E, Pezzoli G. Major nutritional issues in the management of Parkinson's disease. Mov Disord. 2009;24: 1881-1892.
37. Mostile G, Jankovic J. Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Relat Disord. 2009; 3(Suppl):S224-S232.
38. Schoffer KL, Henderson RD, O'Maley K, et al. Nonpharmacological treatment, fludrocortisone and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord. 2007;22:1543-1549.
39. Abate G, Polimeni RM, Cuccurullo F, et al. Effects of indomethacin on postural hypotension in Parkinsonism. BMJ. 1979;2:1466-1468.
40. Wright RA, Kaufmann HC, Perera R. A double-blind, doseresponse study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998;51:120-124.
41. Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003;61:1279-1281.
42. Lagalla G, Millevolte M, Capecci M, et al. Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study. Mov Disord. 2006;21:704-707.
43. Ondo WG, Hunter C, Moore W. A double-blind placebo controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology. 2004;62:37-40.
44. Naumann M, So Y, Argoff CE. Assessment: Botulinum neurotoxin in the treatment of autonom disorders and pain (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1707-1714.
45. Mendonça DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: A randomized controlled trial. Mov Disord. 2007;22:2070-2076.
46. Marín RS. Apathy: A neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3:243-254.
47. Starkstein SE, Leentjens AFG. The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatry. 2008;79:1088-1092.
48. Pluck GC, Brown RG. Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2002;73:636-642.
49. Dujardin K, Sockeel P, Delliaux M. Apathy may herald cognitive decline and dementia in Parkinson's disease. Mov Disord. 2009;24:2391-2397.
50. Brown RG, Pluck G. Negative symptoms: The "pathology" of motivation and goal-directed behavior. Trends Neurosci. 2000;23:412-417.
51. Czernecki V, Pillon B, Houeto JL. Motivation, reward and Parkinson's disease: Influence of dopa therapy. Neuropsychologia. 2002;40:2257-2267.
52. Thobois S, Ardouin CLE. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: Predictors and underlying mesolimbic denervation. Brain. 2010;133:1111-1127.
53. Czernecki V, Schupbach M, Yaici S. Apathy following subthalamic stimulation in Parkinson's disease: A dopamine responsive syndrome. Mov Disord. 2008;23:964-969.
54. Dissanayaka NWN, Sellbach A, Matheson S. Anxiety disorders in Parkinson's Disease: Prevalence and risk factors. Mov Disord. 2010;838-845.
55. Vázquez A, Jiménez-Jiménez FJ, García-Ruiz P. "Panic attacks" in Parkinson's disease: A long-term complication of levodopa therapy. Acta Neurol Scand. 1993;87:14-18.
56. Richard IH, Schiffer RB, Kurlan R. Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1996;8:383-392.
57. Singh A, Althoff R, Martineau J. Pramipexole, ropinirole, and mania in Parkinson's disease. Am J Psychiatry. 2005;162: 814-815.
58. Kulisevsky J, Pascual-Sedano B, Barbanoj M. Acute effects of immediate and controlled release levodopa on mood in Parkinson's disease: A double blind study. Mov Disord. 2006;22:62-67.
59. Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: A randomised, multicentre study. Lancet Neurol. 2008; 7:605-614.
60. Wijtas T, Kaphan E, Regis G. Effects of chronic subthalamic stimulation on non motor fluctuations in Parkinson's disease. Mov Disord. 2007;22:1729-1734.
61. Cummings JL. Depression in Parkinson's disease. Am J Psychiatry. 1992;149:443-454.
62. Ravina B, Camicioli R, Como PG. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007;69:342-347.
63. Remy P, Doder M, Lees A, et al. Depression in Parkinson's disease: Loss of dopamine and noradrenaline innervations in the limbic system. Brain. 2005;128:1314-1322.
64. Miyasaki JM, Shannon K, Voon V. Practice parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:996-1002.
65. Lemke MR. Depressive symptoms in Parkinson's disease. Eur J Neurol. 2008;15(Suppl 1):21-25.
66. Rektorova I, Rektor I, Bares M. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: A national multicentre prospective randomized study. Eur J Neurol. 2003;10:399-406.
67. Barone P, Scarzella L, Marconi R. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: A national multicenter parallel group randomized study. J Neurol. 2006;253:601-607.
68. Pahwa R, Stacy MA, Factor SA. Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68:1108-1115.
69. Barone P, Poewe W, Albrecht S. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573-580.
70. Learned-Coughlin SM, Bergstrom M, Savitcheva I. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry. 2003;54:800-805.
71. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573-580.
72. Charidimou A, Seamons J, Selai C, et al. The role of cognitivebehavioural therapy for patients with depression in Parkinson's disease. Parkinsons Dis. 2011 [Epub ahead of print].
73. Fenelon G, Mahieux F, Huon R. Hallucinations in Parkinson's disease: Prevalence, phenomenology, and risk factors. Brain. 2000;123:733-745.
74. Factor SA, Feustel PJ, Friedman JH. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 2003;60: 1756-1761.
75. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: Focused review and a new integrative model. Mov Disord. 2005;20:130-140.
76. The Parkinson Study G. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999;340:757-763.
77. Kurlan R, Cummings J, Raman R. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68:1356-1363.
78. Friedman JH. Recommendations on the drug treatment of psychosis in Parkinson's disease. Am J Med. 2010;123:e19.
79. Zahodne LB, Fernandez HH. Course, prognosis, and management of psychosis in Parkinson's disease: Are current treatments really effective? CNS Spectr. 2008;13(3 Suppl 4):26-33.
80. Burn D, Emre M, McKeith I. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord. 2006;21:1899-1907.
81. Potenza MN, Voon V, Weintraub D. Drug Insight: Impulse control disorders and dopamine therapies in Parkinson's disease. Nat Clin Pract Neurol. 2007;3:664-672.
82. American Psychiatric A. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. DSM-IV-TR Washington, DC: American Psychiatric Association; 2000.
83. Voon V, Hassan K, Zurowski M. Prospective prevalence of pathological gambling and medication association in Parkinson's disease. Neurology. 2006;66:1750-1752.
84. Weintraub D, Koester J, Potenza MN. Impulse control disorders in Parkinson disease: A cross-sectional study of 3090 patients. Arch Neurol. 2010;67:589-595.
85. Voon V, Thomsen T, Miyasaki JM. Factors associated with dopaminergic drug-related pathological gambling in Parkinson's disease. Arch Neurol. 2007;64:212-216.
86. Pontone G, Williams JR, Bassett SS. Clinical features associated with impulse control disorders in Parkinson disease. Neurology. 2006;67:1258-1261.
87. Voon V, Fernagut PO, Wickens J. Chronic dopaminergic stimulation in Parkinson's disease: From dyskinesias to impulse control disorders. Lancet Neurol. 2009;8:1140-1149.
88. Mamikonyan E, Siderowf AD, Duda JE. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord. 2008;23:75-80.
89. Evans AH, Strafella AP, Weintraub D. Impulsive and compulsive behaviors in Parkinson's Disease. Mov Disord. 2009;24: 1561-1570.
90. Hodgins DC, Petry NM. Cognitive and Behavioral Treatments. In: Grant JE, Potenza MN, eds. Pathological Gambling: A Clinical Guide to Treatment. Washington, DC: American Psychiatric Press; 2004:169-188.
91. Weintraub D, Sohr M, Potenza MN, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol. 2010;68:963-968.
92. Giovanonni G, O'Sullivan J, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68:423-428.
93. O'Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: An overview of its epidemiology, mechanisms and management. CNS Drugs. 2009;23:157-170.
94. Evans AH, Lawrence AD, Potts J, et al. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology. 2005;65:1570-1574.
95. Evans AH, Lawrence AD, Cresswell SA. Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti-reward. Mov Disord. 2010;15:867-876.
96. O'Sullivan SS, Evans AH, Lees AJ. Punding in Parkinson's disease. Pract Neurol. 2007;7:397-399.
97. Evans AH, Katzenschlager R, Paviour D. Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome. Mov Disord. 2004;19:397-405.
98. Lee JY, Kim JM, Kim JW. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord. 2010;16:202-207.
99. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord. 2004;19:1043-1049.
100. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 2010;9:1200-1213.
101. Hely MA, Reid WG, Adena MA, et al. The Sydney Multicenter Study of Parkinson's Disease: The inevitability of dementia at 20 years. Mov Disord. 2008;23:837-844.
102. Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20:190-199.
103. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord. 2005;20:1255-1263.
104. Bohnen NI, Kaufer DI, Ivanco LS. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: An in vivo positron emission tomographic study. Arch Neurol. 2003;60:1745-1748.
105. Kulisevsky J, García-Sánchez C, Berthier ML. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two year follow-up study of previously untreated patients. Mov Disord. 2000;15:613-625.
106. Kulisevsky J, Avila A, Barbajoj M. Acute effects of levodopa on neuropsychological performance in stable and fluctuating PD patients at different levodopa plasma levels. Brain. 1996;119: 2121-2132.
107. Emre M, Aarsland D, Albanese A. Rivastigmine for dementia with Parkinson's disease. What causes mental dysfunction in Parkinson's disease? N Engl J Med. 2004;351:2509-2518.
108. Ravina B, Putt M, Siderowf A. Donepezil for dementia in Parkinson's disease: A randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76:934-939.
109. Aarsland D, Ballard C, Walker Z. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: A double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8:613-618.
110. Anand AR, Onofrj M, Schapira AH. Safi namide potentiates the effects of DA-agonists in early stage Parkinson's disease (PD) patients. Mov Disord. 2007;22(suppl 16):797.
111. Snider Sr, Fahn S, Isgreen WP, et al. Primary sensory symptoms in parkinsonism. Neurology. 1976;26:423-429.
112. Goetz CG, Tanner CM, Levy M, et al. Pain in Parkinson's disease. Mov Disord. 1986;1:45-49.
113. Ford B, Aouise P, Greene P. Oral and genital pain syndromes in Parkinson's disease. Mov Disord. 1996;11:421-426.
114. Quinn NP, Koller WC, Lang AE, et al. Painful Parkinson's disease. Lancet. 1986;1366-1369.
115. Jaaskelainen S, Rinne JO, Forssell H. Role of the dopaminergic system in chronic pain: A fluorodopa-PET study. Pain. 2010; 90:257-260.
116. Vela L, Facca A, Lyons K, et al. Pain and Parkinson's disease. Mov Disord. 2002;17(suppl 5):154-155.
117. Vela L, Lyons K, Singer C, et al. Pain-pressure threshold in patients with Parkinson's disease with and without dyskinesia. Parkinsonism Relat Disord. 2007;13:189-192.
118. Djaldetti R, Shifrin A, Rogowski Z, et al. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology. 2004;62:2171-2175.
119. Brefel-Courbon C, Payoux P, Thalamas C, et al. Effect of levodopa on pain threshold in Parkinsońs disease: A clinical and positron emission tomography study. Mov Disord. 2005;20: 1557-1563.
120. Urakami K, Takahashi K, Matsushima E, et al. The threshold of pain and neurotransmitter's change on pain in Parkinson's disease. J Psychiatry Neurol. 1990;44:589-593.
121. Massetani R, Lucchetti R, Vignocchi G, et al. Pain threshold and polysynaptic components of the blink reflex in Parkinson's disease. Funct Neurol. 1989;4:199-202.
122. Factor S, Brown DL, Molho ES. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease. Mov Disord. 2000;15:167-169.
123. Honey CR, Stoessl AJ, Tsui JKC, et al. Unilateral pallidotomy for reduction of parkinsonian pain. J Neurosurg. 1999;91:198-201.